Tardive Dyskinesia
A condition affecting the nervous system, often caused by long-term use of some psychiatric drugs.
Tardive dyskinesia is caused by long-term use of neuroleptic drugs, which are used to treat psychiatric conditions.
Tardive dyskinesia causes repetitive, involuntary movements, such as grimacing and eye blinking.
Stopping or tapering drugs that may be contributing to involuntary repetitive movements can help. In rare cases, botulinum toxin, deep brain stimulation, or medications can help.
Cluster Number:
Wiki Number: PW216
Diagnosis: Tardive Dyskinesia
US Patients: 30% of those taking antipsychotic medicines
World Patients:
Sex Ratio: M;F+
Age Onset: elderly
Brain Area:
Symptoms: involuntary, repetitive body movements: rapid-jerking or slow-writhing; grimacing, smacking lips, sticking out tongue, eye-blinking
Progression: walking is difficult or impossible due to excess leg movement
Causes: reactions to narcoleptic drugs; reactions to long-term-use of dopamine-receptor-blocking medications; antipsychotics
Medications: supersensitivity to dopamine becomes in the nigrostriatal pathway;discontinuing the narcoleptics helps; valbenazing, etc.
Therapies: No therapies listed; newer antipsychotic drugs cause less dyskinesia than the first generation of antipsychotic drugs did.
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- deutetrabenazine for the treatment of chorea associated with Huntington's diseaseby Harshit Gupta on July 1, 2022
This is a comprehensive review of the literature regarding the use of Deutetrabenazine in treating chorea associated with Huntington's disease. Unfortunately, treatment has been limited for many aspects of this neurodegenerative disease. The present investigation presents the background, evidence, and indications for the use Deutetrabenazine in the setting of Huntington's disease. Huntington's disease is characterized by a variety of motor, psychiatric, and cognitive symptoms with chorea being...
- Prevalence of Tardive Dyskinesia in an Electronic Medical Record Study at a Large Community Mental Health Treatment Centerby Carol S North on June 29, 2022
Objective: To determine the prevalence of tardive dyskinesia (TD) identified by clinicians in naturalistic data in a real-world treatment setting.
- 9-Cyclopropylmethoxy-dihydrotetrabenazine and its stereoisomers as vesicular monoamine transporter-2 inhibitorsby Wenyan Wang on May 31, 2022
Aim: To separate and evaluate 9-cyclopropylmethoxy-dihydrotetrabenazine (13a) and its stereoisomers for their high affinity for vesicular monoamine transporter-2 (VMAT2). Method: Stereoisomers of 13a were separated and configurations were ascertained by chiral chromatography and crystal diffraction combined with ¹H-¹H NOESY assay. Possible binding modes of eight stereoisomers and VMAT2 were explored by molecular docking assays. The VMAT2 affinity of the stereoisomers, inhibition in vivo and...
- Late-Onset Dyskinesia Occurring During Antipsychotic Treatment for Schizophrenia: Treatments for Tardive Dyskinesiaby Masahiro Nomoto on May 19, 2022
Tardive dyskinesia is recognized as buccolingual dyskinesia, but also includes various involuntary movements, such as chorea, dystonia, myoclonus, and tremor. Tardive dyskinesia can be treated depending on the type of movement disorder present. Antipsychotics causing tardive dyskinesia should be reduced in dosage or should be discontinued. However, the treatment of schizophrenia is important, and neurologists must treat tardive dyskinesia in collaboration with psychiatrists taking care of...